Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

KalVista Pharmaceuticals (KALV) Other Non-Current Liabilities: 2014-2024

  • KalVista Pharmaceuticals' Other Non-Current Liabilities was N/A to $99.9 million in Q4 2024 from the same period last year, while for Dec 2024 it was $99.9 million, marking a year-over-year change of. This contributed to the annual value of $1.5 million for FY2014, which is N/A change from last year.
  • As of Q4 2024, KalVista Pharmaceuticals' Other Non-Current Liabilities stood at $99.9 million, which was up 4,268.43% from $2.3 million recorded in Q1 2015.
  • In the past 5 years, KalVista Pharmaceuticals' Other Non-Current Liabilities ranged from a high of $99.9 million in Q4 2024 and a low of $99.9 million during Q4 2024.
  • Its 1-year average for Other Non-Current Liabilities is $99.9 million, with a median of $99.9 million in 2024.